99 POSTER Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation
R. Wooster, W. Cornwell, J. Jing, J. Greshock, A. Gilmartin, D. Sutton, J. Jackson, S. Laquerre, B. Weber, Y. DegenhardtVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72031-7
File:
PDF, 74 KB
english, 2008